FBRX
NASDAQForte Biosciences Inc.
News · 26 weeks55-17%
2026-03-012026-08-23
Mix3690d
- SEC Filings11(31%)
- Other11(31%)
- Insider10(28%)
- Earnings3(8%)
- Analyst1(3%)
Latest news
25 items- SECAmendment: SEC Form SC 14D9/A filed by Forte Biosciences Inc.SC 14D9/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by Forte Biosciences Inc.SC 14D9/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECSEC Form 10-Q filed by Forte Biosciences Inc.10-Q - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form SCHEDULE 13G filed by Forte Biosciences Inc.SCHEDULE 13G - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- PRargenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a tender offer to purchase all of the issued and outstanding shares of Common Stock, par value $0.001 per share (the "Shares"), of Forte Biosciences, Inc. ("Forte") (NASDAQ:FBRX), for $77.00 per Share, net to the seller in cash, without interest, subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 6, 2026, and the accompanying Letter of Transmittal (to
- SECSEC Form SC 14D9 filed by Forte Biosciences Inc.SC 14D9 - Forte Biosciences, Inc. (0001419041) (Subject)
- SECSEC Form SC14D9C filed by Forte Biosciences Inc.SC14D9C - Forte Biosciences, Inc. (0001419041) (Subject)
- SECSEC Form SC14D9C filed by Forte Biosciences Inc.SC14D9C - Forte Biosciences, Inc. (0001419041) (Subject)
- SECForte Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- PRargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology PipelineTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation Acquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction argenx ((Euronext &, NASDAQ:ARGX), a global immunol
- PRargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology PipelineTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growthFB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovationAcquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biologyargenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction July 27, 2026 – 7:00 AM CET Amsterdam, the Netherlands and Dalla
- ANALYSTBarclays initiated coverage on Forte Biosciences with a new price targetBarclays initiated coverage of Forte Biosciences with a rating of Overweight and set a new price target of $74.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECForte Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- PRFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment PeriodStatistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24 FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2– and IL-15–Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.57% to 42,600 units (SEC Form 4)4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDEROfficer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 85,482 units (SEC Form 4)4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF FINANCIAL OFFICER Riley Antony A4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Officer Wagner Paul A.4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form EFFECT filed by Forte Biosciences Inc.EFFECT - Forte Biosciences, Inc. (0001419041) (Filer)
FBRX FAQ
7 questionsWhat does Forte Biosciences Inc. do?
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.Where does FBRX stock trade?
Forte Biosciences Inc. (FBRX) is listed on NASDAQ.What sector and industry is FBRX in?
Forte Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Forte Biosciences Inc. go public?
Forte Biosciences Inc. (FBRX) completed its IPO in 2017.What are analysts saying about FBRX?
Forte Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-07-21. Recent price targets range from $275.00 to $350.00.What companies are similar to FBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare FBRX side-by-side with any of them on Quantisnow.How can I track FBRX on Quantisnow?
Quantisnow aggregates Forte Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FBRX to receive live email and push alerts on every new disclosure.